Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details)

v3.20.2
Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Cash $ 9,066   $ 9,066   $ 17,767
Accounts receivable, net 174,641   174,641   482,472
Prepaid expenses and other current assets 2,575   2,575   5,150
Current assets classified as held for sale 186,282   186,282   505,389
Property and equipment, net 1,168   1,168   3,354
Deposits 100,014   100,014   106,043
Right of use assets 122,898   122,898   185,842
Non-current assets classified as held for sale 224,080   224,080   295,239
Accounts payable 1,765,073   1,765,073   2,041,628
Accrued expenses 1,569,694   1,569,694   1,714,789
Current portion of right-of-use operating lease obligations 96,334   96,334   85,726
Current portion of notes payable 238,018   238,018   256,274
Current liabilities classified as held for sale 3,669,119   3,669,119   4,098,417
Right-of-use operating lease obligations 1,280,006   1,280,006   1,208,323
Liabilities classified as held for sale 26,564   26,564   100,116
Revenue from services 174,941 $ 212,046 437,560 $ 748,561  
Cost of services 390 26,012 11,379 117,248  
Gross profit 174,551 186,034 426,181 631,313  
Operating expenses 300,149 444,930 616,693 1,866,703  
Other expense 40,582 2,912 (26,219) 31,374  
Provision for income taxes  
Loss from discontinued operations (166,180) (261,808) (164,293) (1,266,764)  
Advanced Molecular Services Group and Health Technology Solutions, Inc [Member]          
Cash 9,066   9,066   17,767
Accounts receivable, net 174,641   174,641   482,472
Prepaid expenses and other current assets 2,575   2,575   5,150
Current assets classified as held for sale 186,282   186,282   505,389
Property and equipment, net 1,168   1,168   3,354
Deposits     6,029
Right of use assets    
Non-current assets classified as held for sale 1,168   1,168   9,383
Accounts payable 946,161   946,161   1,160,101
Accrued expenses 1,286,326   1,286,326   1,376,127
Current portion of right-of-use operating lease obligations    
Current portion of notes payable 238,018   238,018   256,274
Current liabilities classified as held for sale 2,470,505   2,470,505   2,792,502
Revenue from services 174,941 246,676 437,119 766,627  
Cost of services 390 26,012 11,379 113,266  
Gross profit 174,551 220,664 425,740 653,361  
Operating expenses 258,789 355,828 509,989 1,413,423  
Other expense 37,476 2,912 61,067 31,874  
Provision for income taxes  
Loss from discontinued operations (121,714) (138,076) (145,316) (791,936)  
EPIC Reference Labs, Inc. [Member]          
Cash 9,057   9,057  
Accounts receivable, net 174,641   174,641  
Prepaid expenses and other current assets 2,575   2,575  
Current assets classified as held for sale 186,273   186,273  
Property and equipment, net    
Deposits 100,014   100,014   100,014
Right of use assets 122,898   122,898   185,842
Non-current assets classified as held for sale 222,912   222,912   285,856
Accounts payable 818,912   818,912   881,527
Accrued expenses 283,368   283,368   338,662
Current portion of right-of-use operating lease obligations 96,334   96,334   85,726
Current portion of notes payable    
Current liabilities classified as held for sale 1,198,614   1,198,614   1,305,915
Right-of-use operating lease obligations 26,564   26,564   100,116
Liabilities classified as held for sale 26,564   26,564   $ 100,116
Revenue from services [1] (34,630) 441 (18,066)  
Cost of services 3,982  
Gross profit (34,630) 441 (22,048)  
Operating expenses 41,360 89,102 106,704 453,280  
Other expense 3,106 (87,286) (500)  
Provision for income taxes  
Loss from discontinued operations $ (41,360) $ (123,732) $ (18,977) $ (474,828)  
[1] The Company recorded bad debts in excess of gross revenues in the three months ended September 30, 2019.